4 Participants Needed

New Imaging Technique for Pancreatic Cancer

Recruiting at 9 trial locations
NP
JL
Overseen ByJason Lewis, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new imaging substance called 89Zr-DFO-HuMab-5B1. It aims to help doctors see pancreatic tumors more clearly during scans. The study focuses on people with pancreatic cancer to improve how well these tumors can be seen.

Who Is on the Research Team?

Neeta Pandit-Taskar, MD - MSK Nuclear ...

Neeta Pandit-Taskar, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with advanced pancreatic cancer or tumors that show a marker called CA19-9. They must be scheduled for surgery, have certain blood and organ function levels within set limits, and not be pregnant or breastfeeding. People with major recent surgeries, uncontrolled infections, HIV, or severe psychiatric issues cannot join.

Inclusion Criteria

Signed, informed consent
My CA19-9 levels are above normal, or my biopsy was CA19-9 positive.
I have a tumor that is at least 2 cm large, visible on CT or MRI.
See 10 more

Exclusion Criteria

You had a severe allergic reaction to a specific type of medication made from human or humanized antibodies.
Prior entry onto this protocol 3 or more times (e.g., subjects may enter this protocol and be imaged up to 3 times)
Pregnant or currently breast-feeding
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging

Participants receive a single, fixed, intravenous dose of MVT-2163 for imaging purposes

1 day
1 visit (in-person)

Follow-up

Participants are monitored for treatment-related adverse events and biodistribution of MVT-2163

1 year

What Are the Treatments Tested in This Trial?

Interventions

  • 89Zr-DFO-HuMab-5B1
Trial Overview The study tests an experimental imaging agent named 89Zr-DFO-HuMab-5B1 to see how well it attaches to pancreatic tumors during PET/CT scans. The goal is to improve the quality of tumor images in patients who are about to undergo surgery.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: 89Zr-DFO-HuMab-5B1 (MVT-2163) ImagingExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

BioNTech SE

Industry Sponsor

Trials
84
Recruited
120,000+

Prof. Dr. Ugur Sahin

BioNTech SE

Chief Executive Officer since 2008

MD from University of Cologne

Prof. Özlem Türeci

BioNTech SE

Chief Medical Officer since 2018

MD from Saarland University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security